Warfarin pharmacogenetics: It matters if you're black or white

Blood

Volumn 124, Issue 14, 2014, Pages 2171-

  Wadelius, Mia ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; FOLYLPOLYGLUTAMATE SYNTHASE; MITOCHONDRIAL ENZYME; WARFARIN; ANTICOAGULANT AGENT; FOLIC ACID;

AFRICAN AMERICAN; ALGORITHM; ANTICOAGULANT THERAPY; CAUCASIAN; CHROMOSOME 10; CHROMOSOME 9; DOSE RESPONSE; DRUG MEGADOSE; EXOME; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; REVIEW; SEQUENCE ANALYSIS; GENETICS; HOMEOSTASIS; METABOLISM;

AFRICAN AMERICANS; ANTICOAGULANTS; FOLIC ACID; HOMEOSTASIS; HUMANS; WARFARIN;

EID: 84907698416     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-08-594119     Document Type: Review

References (10)

1. Daneshjou R, Gamazon ER, Burkley B, et al. Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. Blood. 2014;124(14):2298-2305.
2. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353(9154):717-719.
3. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005;105(2):645-649.
4. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008; 84(3):326-331.
5. Klein TE, Altman RB, Eriksson N, et al; International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753-764.
6. Limdi NA, Wadelius M, Cavallari L, et al; International Warfarin Pharmacogenetics Consortium. Warfarin pharmacogenetics: A single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood. 2010; 115(18):3827-3834.
7. Pirmohamed M, Burnside G, Eriksson N, et al; EU-PACT Group. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369(24):2294-2303.
8. Kimmel SE, French B, Kasner SE, et al; COAG Investigators. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl JMed. 2013;369(24):2283-2293.
9. Perera MA, Cavallari LH, Limdi NA, et al. Genetic variants associated with warfarin dose in African-American individuals: A genome-wide association study. Lancet. 2013; 382(9894):790-796.
10. Leil TA, Endo C, Adjei AA, et al. Identification and characterization of genetic variation in the folylpolyglutamate synthase gene. Cancer Res. 2007;67(18):8772-8782.